Global Health Investment Fund leads $7.5 million partnership to boost access to low-cost oral cholera vaccine

Aug 29, 2014

The Global Health Investment Fund (“GHIF”), an innovative financing vehicle structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, has launched a new partnership to support the final development and distribution of a new oral cholera vaccine for those who need it most. The vaccine, called Euvichol, is poised to become the second World Health Organization prequalified oral cholera vaccine suitable for use in the low- and middle-income countries where cholera still exacts an unacceptable toll on public health and economic productivity.

EuBiologics Co., Ltd. (“EuB”), a Korean biopharmaceutical company focused on delivering vaccine products and contract manufacturing services to improve global public health, has committed to manufacture a new and improved presentation of the vaccine at a target price of $1.00 per dose for public sector buyers. This is 45% lower than the minimum price currently offered to public sector purchasers, and EuB’s annual manufacturing capacity will be as much as five-times greater than the current global supply.

Read the press release.


Copyright © 2020 JPMorgan Chase & Co. All rights reserved.